Delving into the Latest Updates on Carvedilol with Synapse

Overview

Basic Info

SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions.

Drug Type

Small molecule drug

Synonyms

Carvedilol (JP17/USP/INN), Corever, Pluscor

+ [28]

Target

ADRA1 x adrenergic receptor x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesUrogenital Diseases+ [1]

Active Indication

Atrial FibrillationAngina, StableHeart Failure+ [5]

Inactive Indication

Chronic heart failureDrug Resistant EpilepsyHypertrophy, Left Ventricular+ [4]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

InnoPharmax, Inc.Alvogen Korea Co., Ltd.

Daiichi Sankyo Co., Ltd.

+ [1]

Inactive Organization

TSH Biopharm Corp., Ltd.

Chong Kun Dang Pharmaceutical Corp.

GSK Plc

+ [1]

Drug Highest PhaseApproved

First Approval Date

JP (19 Jan 1993),

Angina PectorisEssential HypertensionHypertension, Renal

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H26N2O4

InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N

CAS Registry72956-09-3

Brief summaries of CZXH-PH-ALV-2403 The goal of this clinical trial is to learn if the combination of alverine and carvedilol works to treat portal hypertension in adult patients with liver cirrhosis. It will also learn about the safety of alverine.
The main question it aims to answer is:
For patients with liver cirrhosis and portal hypertension who have been treated with carvedilol at a dose of up to 15 mg/day or at a lower dose that is the maximum tolerated for at least 3 months, and still have a hepatic venous pressure gradient (HVPG) of 12 mmHg or higher and up to and including 20 mmHg, can the addition of alverine help to reduce portal hypertension? On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.

Start Date15 Nov 2024

Sponsor / Collaborator

Shanghai Changzheng Hospital

[+1]

ChiCTR2400089692

/ SuspendedPhase 4IIT

Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of esophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial.

Start Date01 Nov 2024

Sponsor / Collaborator

The First Hospital Of China Medical University

NCT06594783

/ Not yet recruitingPhase 4IIT

Carvedilol Plus Endoscopic Ligation or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders: a Randomized Controlled Trial

The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol non-responders. It will also learn about the safety of carvedilol combined with EVL in patients with cirrhosis.
The main questions it aims to answer are:
Whether carvedilol plus EVL is more effective than carvedilol alone in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol.
What medical problems do participants have when taking carvedilol or taking carvedilol combined with undergoing EVL? Researchers will compare the efficacy and safety of carvedilol with or without EVL in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol.
Participants will:
Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol, or Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
Visit the clinic once every 2-3 months for checkups and tests. Keep a diary of their vital signs (SBP, DBP, and HR) as well as symptoms.

Start Date01 Oct 2024

Sponsor / Collaborator

Taipei Veterans General Hospital

100 Clinical Results associated with Carvedilol

Login to view more data

100 Translational Medicine associated with Carvedilol

Login to view more data

100 Patents (Medical) associated with Carvedilol

Login to view more data

3,919

Literatures (Medical) associated with Carvedilol

01 Feb 2025·Redox Biology

Oxidative stress promotes lipid-laden macrophage formation via CYP1B1

Article

Author: Wang, Xiaoyun ; Owen, Caroline A ; Somanath, Payaningal R ; Han, Yohan ; Polverino, Francesca ; Zhu, Yin ; Choi, Dooyoung ; Zhang, Duo ; Dutta, Saugata

Emerging evidence suggests that lipid-laden macrophages (LLM) participate in lung damage in various clinical conditions. However, the mechanisms involved in LLM formation are not fully understood. In this study, we aimed to investigate the link between reactive oxygen species (ROS) and LLM formation. We found that ROS triggered by cigarette smoke extract (CSE) or H₂O₂ significantly promoted LLM formation. Given the key role of ROS in LLM formation, we further demonstrated that LLM formation is induced by various ROS-producing stimuli, including bacteria, oxidized low-density lipoprotein (OxLDL), hyperoxia, and E-cigarette vapor extract (EVE). Meanwhile, cytochrome P450 family-1 subfamily B member 1 (CYP1B1) was highly upregulated in lung macrophages from chronic obstructive pulmonary disease (COPD) patients and CSE-treated macrophages. Functionally, CYP1B1 contributes to the CSE-induced lipid accumulation and LLM formation. CYP1B1 expression and LLM formation were effectively suppressed by antioxidant N-acetylcysteine (NAC) and carvedilol. The formation of LLM was also associated with classically activated M1 but not the M2 state. CSE-induced LLM showed time-dependent alterations in inflammatory response and phagocytic ability. In summary, our study highlights the role of oxidative stress in LLM formation. CYP1B1 contributes to ROS-induced LLM formation and may serve as a therapeutic target for reducing LLM-induced lung damage.

01 Jan 2025·British Journal of Pharmacology

Carvedilol inhibits neuronal hyperexcitability caused by epilepsy‐associated KCNT1 mutations

Article

Author: Wu, Tong ; Chen, Jiexin ; Huang, Zhuo ; Zhang, Xinran ; Song, Huifang ; Sun, Haojie ; Shah, Mala ; Li, Na ; Jiang, Yuwu ; Gao, Kai ; Yi, Jingyun ; Di, Chang ; Wang, Lili

Background and Purpose:

KCNT1 encodes a sodium‐activated potassium channel (Slack channel), and its mutation can cause several forms of epilepsy. Traditional antiepileptic medications have limited efficacy in treating patients with KCNT1 mutations. Here, we describe one heterozygous KCNT1 mutation, M267T, in a patient with EIMFS. The pathological channel properties of this mutation and its effect on neuronal excitability were investigated. Additionally, this study aimed to develop a medication for effective prevention of KCNT1 mutation‐induced seizures.

Experimental Approach:

Wild‐type or mutant KCNT1 plasmids were expressed heterologously in Xenopus laevis oocytes, and channel property assessment and drug screening were performed based on two‐electrode voltage‐clamp recordings. The single‐channel properties were investigated using the excised inside‐out patches from HEK293T cells. Through in utero electroporation, WT and M267T Slack channels were expressed in the hippocampal CA1 pyramidal neurons in male mice, followed by the examination of the electrical properties using the whole‐cell current‐clamp technique. The kainic acid‐induced epilepsy model in male mice was used to evalute the antiseizure effects of carvedilol.

Key Results:

The KCNT1 M267T mutation enhanced Slack channel function by increasing single‐channel open probability. Through screening 16 FDA‐approved ion channel blockers, we found that carvedilol effectively reversed the mutation‐induced gain‐of‐function channel properties. Notably, the KCNT1 M267T mutation in the mouse hippocampal CA1 pyramidal neurons affected afterhyperpolarization properties and induced neuronal hyperexcitability, which was inhibited by carvedilol. Additionally, carvedilol exhibited antiseizure effects in the kainic acid‐induced epilepsy model.

Conclusion and Implication:

Our findings suggest carvedilol as a new potential candidate for treatment of epilepsies.

01 Jan 2025·Clinical Journal of the American Society of Nephrology

Comparative Effectiveness of Bisoprolol, Carvedilol, and Metoprolol Succinate in Patients with Heart Failure and CKD

Article

Author: Shaw, Sally F. ; Yu, Albert S. ; Shi, Jiaxiao ; Pak, Katherine ; Zhou, Hui ; Huang, Cheng-Wei ; Broder, Benjamin I. ; Sim, John J.

17

News (Medical) associated with Carvedilol

15 Feb 2024

·www.businesswire.com

GoodRx Now Offering 30 Common Heart Health Medications for Under $30

SANTA MONICA, Calif.--( BUSINESS WIRE )-- GoodRx , the leading destination for prescription savings in the U.S., today announced it is offering 30 of the most common heart health medications for under $30 at more than 70,000 pharmacies nationwide. 1 Cardiovascular disease is one of the most prominent conditions facing Americans, affecting nearly half of all U.S. adults. That’s why GoodRx is making it easier for all individuals, regardless of insurance status, to access savings on both generic and brand-name medications that mitigate the risk and impact of cardiovascular conditions such as coronary artery disease, high cholesterol, hypertension, and more. By helping people afford their prescriptions, GoodRx is improving health outcomes and reducing the overall strain on the healthcare system. GoodRx’s recent report - The GoodRx Effect - estimates that GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits and 110,000 hospitalizations for major adverse cardiovascular events like heart attack and stroke. Save an average of 84% on common generic medications 2 The following is a sample list of common generic medications used to treat cardiovascular disease that are available for under $30 on GoodRx. MEDICATION LOWEST PRICE 3 AVG % SAVINGS 4 ACE Inhibitors Lisinopril (generic Prinivil and Zestril) $9.29 67% Enalapril (generic Epaned and Vasotec) $15.54 75% Beta Blockers Carvedilol (generic Coreg) $10.68 75% Metoprolol ER (generic Toprol XL) $11.15 74% Propranolol (generic Inderal) $10.96 71% Calcium Channel Blockers Amlodipine (generic Amvaz, Katerzia, and Norvasc) $9.15 80% Diltiazem ER (generic Cardizem CD) $13.43 74% Statins Atorvastatin (generic Lipitor) $10.10 83% Pravastatin (generic Pravachol) $14.53 74% Rosuvastatin (generic Crestor) $10.57 91% Access exclusive discounts and savings on brand-name drugs GoodRx offers incredible savings on brand-name medications that are often more costly and harder to obtain: MEDICATION SAVINGS* Entresto Pay as little as $10 for up to a 90-day supply Jardiance Pay as little as $10 per month Lodoco Pay as little as $30 for up to a 90-day supply Ozempic Pay as little as $25 per month Repatha Pay as little as $5 per month Soaanz Exclusive discount to save over 70% Toprol XL Exclusive discount to save up to 51% Xarelto Pay as little as $10 per fill *May require private or commercial insurance Learn more about cardiovascular disease from trusted doctors, pharmacists and health experts GoodRx Health is a go-to resource for understanding common heart conditions, risk factors, treatment options and associated savings. The GoodRx Heart Health Center provides credible, timely and actionable information to help people better manage their health. Each article is researched and written by a team of editorial experts, and clinical content is reviewed by a team of medical experts that includes physicians, pharmacists, and more. “Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD , Medical Editor at GoodRx. “Knowledge is power, so we create easy-to-understand content that people can actually use so they are better equipped to minimize the risk of disease, find affordable medications, stick to their treatment plans, and ultimately improve their overall health and wellbeing.” To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com/hearthealth . About GoodRx GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save more than $65 billion and is one of the most downloaded medical apps over the past decade. GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com . We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the benefits of our offerings to consumers, the U.S. healthcare system and GoodRx; and GoodRx’s plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. 1 Prices are subject to change at any time without notice. Prices may vary at different pharmacies, and for different forms, dosages, and quantities. 2 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023. 3 As of February 1, 2024. 4 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023.

AHA

12 Jan 2024

·www.drugs.com

Drug May Help Childhood Cancer Survivors Avoid Later Heart Failure

FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives. But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal . A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo. “The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian , chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles. “Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer-free,” Armenian added in a City of Hope news release. The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs. The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge. Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts. Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic. The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years. The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show. However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health. Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said. “The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said. Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said. Sources City of Hope, news release, Jan. 9, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalPhase 3

12 Jan 2024

·www.drugs.com

Carvedilol May Help Childhood Cancer Survivors Avoid Later Heart Failure

FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives. But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal . A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo. “The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian , chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles. “Just helping children survive cancer isn’t enough. We also need to optimize patients’ health so that they don’t have to face life-threatening side effects decades after they are cancer-free,” Armenian added in a City of Hope news release. The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs. The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge. Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts. Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic. The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years. The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show. However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health. Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said. “The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said. Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said. Sources City of Hope, news release, Jan. 9, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalPhase 3

100 Deals associated with Carvedilol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00255	Carvedilol	C07AG02	DB01136

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Atrial Fibrillation	JP	Daiichi Sankyo Co., Ltd.	24 Aug 2015
Myocardial Infarction	US	Sun Pharmaceutical Industries, Inc.	05 Sep 2007
Angina, Stable	KR	Alvogen Korea Co., Ltd.	06 Nov 2001
Heart Failure	US	Waylis Therapeutics LLC	14 Sep 1995
Hypertension	US	Waylis Therapeutics LLC	14 Sep 1995
Ventricular Dysfunction, Left	US	Waylis Therapeutics LLC	14 Sep 1995
Angina Pectoris	JP	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Essential Hypertension	JP	Daiichi Sankyo Co., Ltd.	19 Jan 1993
Hypertension, Renal	JP	Daiichi Sankyo Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Drug Resistant Epilepsy	Phase 3	US	GSK Plc	01 Dec 2008
Left ventricular systolic dysfunction	Phase 3	US	GSK Plc	01 Oct 2005
Hypertrophy, Left Ventricular	Phase 3	US	GSK Plc	01 Jan 2005
Chronic heart failure	Phase 3	US	GSK Plc	01 Jan 2002
Pulmonary Arterial Hypertension	Phase 2	US	GSK Plc	01 Jun 2010
Metabolic Syndrome	Phase 1	GB	GSK Plc	15 Jan 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Not Applicable	Coronary Vasospasm	-	Carvedilol 2.5mg/kg	tjdiymusvh(qsqqivpjbo) = wnvnhiylgi qfvfzpspgk (zpdjhysfez )	-	30 Aug 2024
				Propranolol 20mg/kg	tjdiymusvh(qsqqivpjbo) = umgqvnrofz qfvfzpspgk (zpdjhysfez )
NCT03069339 (CAVARLY, Pubmed) Manual	Not Applicable	Esophageal and Gastric Varices \| Liver Cirrhosis	330	Combination of carvedilol and VBL	zehpepfdcl(qocrkvwwmo) = dgpdlslltj hcpkmnxvka (jyxqjqafei ) View more	Positive	27 Jul 2024
NCT00430040 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Inflammation \| Hypertension ... View more	14	lisinopril+Carvedilol Controlled Release (CR) (Carvedilol)	xezjalnoal(ojagcppbvv) = bqghbbqccf vbppxnxmlx (kdqmacfzef, znoylmtkcn - twfnjnsvyb) View more	-	16 Apr 2024
				lisinopril (Lisinopril)	xezjalnoal(ojagcppbvv) = ckigbgiilw vbppxnxmlx (kdqmacfzef, qcpvcdeynu - ckomwxhdjt) View more
NCT03736265 (Pubmed) Manual	Not Applicable	Compensated cirrhosis Add-on	205	nucleos(t)ide analog	zeldqypurd(nqedhyutol) = wlxylvwiaf gjiyunsvde (etotmokybe ) View more	Negative	01 Apr 2024
				Carvedilol 12.5 mg + nucleos(t)ide analog	zeldqypurd(nqedhyutol) = udynmqpblk gjiyunsvde (etotmokybe ) View more
DOPPS (ISN WCN2024)	Not Applicable	Maintenance	-	Metoprolol	dgboecieuf(csxpcltlou): P-Value = 0.83	Positive	01 Apr 2024
				Atenolol
NCT02717507 (PREVENT-HF, Literature) Manual	Phase 2	Heart Failure	182	carvedilol	ffxdrgolbi(rgggoyugga) = lqsrkixndj zxixrkqwlo (izgdyhzygl, −0.43 - 0.16) View more	Positive	09 Jan 2024
				placebo	ffxdrgolbi(rgggoyugga) = ulckesrajz zxixrkqwlo (izgdyhzygl, −0.77 - −0.13) View more
NCT00642434 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Hyperglycemia \| Hypertension ... View more	22	Metoprolol (Metoprolol)	qbhhxrtcgu(pithwanplc) = hzihbixqwo mizgpszdtq (jbeedehpec, aonqpumexf - jhcqacyulg) View more	-	26 Dec 2023
				Carvedilol (Carvedilol)	qbhhxrtcgu(pithwanplc) = sansalblqk mizgpszdtq (jbeedehpec, fnkkajvhku - lemurgqamr) View more
NCT03736265 (AASLD2023)	Not Applicable	Hepatitis B \| Fibrosis Add-on	238	NUCs	coqlbrbkwa(tzqfgmkwfh) = skqhzbihto hjfradtluw (sbrnqjjtic, 0.36 - 1.77)	Positive	10 Nov 2023
				Carvedilol plus NUCs	coqlbrbkwa(tzqfgmkwfh) = ubsdmgfszi hjfradtluw (sbrnqjjtic, 0.36 - 1.77)
NCT02717507 (PREVENT-HF \| COG ALTE1621, CTgov)	Phase 2	Malignant Solid Neoplasm \| Heart Failure \| Hematologic Neoplasms	196	Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol))	xqqjfrtzzk(sfpizuwmfz) = xmseddggod uvbzwrxznx (nowhnobbmf, cbhzukwamo - tkahrwsugo) View more	-	29 Sep 2023
				Pharmacogenomic Study (Arm II (Placebo))	xqqjfrtzzk(sfpizuwmfz) = ligkkfzcqn uvbzwrxznx (nowhnobbmf, bnehhvqlqd - bigbtiiqpf) View more
NCT01155635 (CAPITAL-RCT, Pubmed \| Am J Cardiol)	Phase 4	ST Elevation Myocardial Infarction	794	Carvedilol	ziovgesyyw(bnvvrudymm) = zuwbedxvwk wcbyrxupmq (nmwyfumgvs ) View more	-	01 Jul 2023
				No β-blocker therapy	ziovgesyyw(bnvvrudymm) = sumrzraite wcbyrxupmq (nmwyfumgvs ) View more